The Boston Biomedical Innovation Center (B-BIC) is a consortium of academia, non-profits, government, industry, and venture capital designed to accelerate translation of early stage biomedical innovations into commercially viable products.
As an NIH National Center for Accelerated Innovation (NCAI), B-BIC provides grant funding, project management, coaching, and skills development to academic investigators for the development of devices, diagnostics, and therapeutics addressing heart, lung, blood, and sleep disorders.
B-BIC DRIVE grants provide up to $200,000 for direct costs, with significant involvement from the Center, to support milestone-based projects. DRIVE projects may take 18 - 24 months and are expected to include proof-of-value and validation studies for commercial translation of the technology.
B-BIC offers Pilot grants up to $50,000 to support direct costs for one year. Pilot projects may include feasibility studies as well as experiments to test the reproducibility of hypothesis-driven research with a goal of developing the commercial value of the technology.
PROJECT MANAGEMENT AND COACHING
B-BIC provides project management support to investigators and teams to help advance funded projects towards commercialization goals. B-BIC’s Project Managers (PMs) provide a breadth of academic and industry experience in the development and commercialization of medical devices, diagnostics and therapeutics, enabling the PMs to provide critical support to the project teams.
B-BIC connects innovators to courses, workshops, expert advisors and community events focused on technology commercialization. B-BIC project funding also provides access to highly customized support from the Skills Development Center (SDC) through the creation and facilitation of individualized skills development plans. This support is expected to enhance the development of the entrepreneurial skills needed by academic investigators as they enter into the commercial landscape.
B-BIC provides access to key partners by providing access and facilitating meetings between project teams and the Food and Drug Administration (FDA), the Center for Medicare and Medicaid Services (CMS), the U.S. Patent and Trade Office (USPTO), relevant companies and organizations in industry, and the Angel and venture capital investment communities.